Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (71)

2024

  1. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78

  2. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study

    Lupus

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Gender biases in Spanish rheumatology: Perception and facts

    Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401

  3. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  4. Searching for a prognostic index in lupus nephritis

    European journal of medical research, Vol. 28, Núm. 1, pp. 19

  5. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

  6. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Importance of family planning in patients with immune-mediated inflammatory diseases: a multidisciplinary approach

    Reumatologia Clinica, Vol. 18, Núm. 4, pp. 200-206

  3. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 9, pp. 1337-1338

  4. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines

    European Journal of Internal Medicine, Vol. 99, pp. 19-21

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

  3. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER)

    Reumatologia Clinica, Vol. 17, Núm. 2, pp. 61-66

  4. Pregnancy control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 183-186

  5. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 125-131

  6. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  7. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

  8. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 6, pp. 1258-1262